Jump to content
RemedySpot.com

Some people naive to isentress may have integrase resistance mutations

Rate this topic


Recommended Posts

Posted

..Antimicrob Agents Chemother. 2010 Dec 20. [Epub ahead of print]Analysis of low frequency mutations associated with drug-resistance to raltegravir before antiretroviral treatment.

Liu J,  MD, Danovich RM, Vandergrift N, Cai F, Hicks CB, Hazuda DJ, Gao F.

Duke Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA; Merck & Co., Inc., West Point, PA, USA; Department of Microbiology, Peking University Health Science Center, Beijing 100191, China.

AbstractRaltegravir is highly efficacious in the treatment of HIV infection. The prevalence and impact on virologic outcome of low frequency resistant mutations among HIV-infected patients not previously treated with raltegravir have not been fully established. Samples from HIV treatment-experienced patients entering a clinical trial of raltegravir treatment (BENCHMRK) were analyzed using a parallel allele-specific sequencing (PASS) assay that assessed six primary and six secondary integrase mutations. Patients who achieved and sustained virologic suppression (success patients, n=36) and those who experienced virologic rebound (failure patients, n=35) were compared. Patients who experienced treatment failure had twice as many raltegravir-associated resistance mutations prior to initiating treatment compared to those who achieved sustained virologic success, but the difference was not statistically significant. The frequency of nearly all detected resistance mutations was less than 1% of viral population and the frequencies of mutations between the success and failure groups were similar. Expansion of pre-existing mutations (one primary and five secondary) was observed in 16 treatment-failure patients in whom minority resistant mutations were detected at baseline, suggesting that they might play a role in the development of drug resistance. Two or more mutations were found in 13 patients (18.3%), but multiple mutations were not present in any single viral genome by linkage analysis. Low frequency primary RAL-resistant mutations are uncommon while minority secondary RAL-resistant mutations were more frequently detected in patients naïve to raltegravir. Additional studies in larger populations are warranted to fully understand the clinical implications of these mutations.

-- Greetings, VergelAmazon Author profile: http://www.amazon.com/-/e/B003E3RYKY

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...